Founded in 2008, Immunophotonics is dedicated to pioneering immunotherapy-based treatments for cancer. The company's core mission is to unlock the potential of the immune system with a new class of therapeutics, focusing on minimally invasive therapeutic cancer vaccines for metastatic solid tumors. Their product pipeline targets various cancers, including colorectal cancer, non-small cell lung cancer, melanoma, soft tissue sarcoma, hepatocellular carcinoma, and pancreatic cancer. Immunophotonics operates from Columbia, Missouri, and collaborates strategically with Veterinary Cancer Therapeutics, LLC.
Notable figures associated with Immunophotonics include its co-inventors and a distinguished board of directors and advisory board members. The company has achieved significant milestones in developing its interventional immuno-oncology therapies, contributing to advancements in cancer treatment. Through its innovative approach, Immunophotonics has made a substantial impact on the field of oncology, offering new hope for patients with metastatic solid tumors.
